insights_auto
Why is PHIO down 3.11%?
Dive Deeperchevron_right
PHIO:NASDAQ
Phio Pharmaceuticals Corp
$0.81
arrow_downward
-3.11%(-0.026) 1D
$0.80
arrow_downward
-1.70% (-0.014)bedtimeAfter hours
Closed: Nov 10, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PHIO...
Open
$0.80
High
$0.86
Low
$0.79
Mkt. cap
9.73M
Avg. vol.
76.71K
Volume
0.00
52-wk high
$1.88
52-wk low
$0.75
EPS
-$1.39
Beta
0.93
Shares outstanding
11.95M
No. of employees
6
Open
$0.80
High
$0.86
Low
$0.79
Mkt. cap
9.73M
Avg. vol.
76.71K
Volume
0.00
52-wk high
$1.88
52-wk low
$0.75
EPS
-$1.39
Beta
0.93
Shares outstanding
11.95M
No. of employees
6
News stories
From web sources and news partners
Investing.com
·
11 hours ago
Phio Pharmaceuticals director ronald plott acquires $15,189 in shares
Investing.com
·
11 hours ago
Phio Pharmaceuticals CEO Robert Bitterman buys $20,500 in stock
Investing.com India
·
12 hours ago
Form 4 Phio Pharmaceuticals Corp: Robert J. Bitterman (Director, Chairman, Pres. & CEO) For: 9 November
Quantisnow
·
12 hours ago
Phio Pharmaceuticals (PHIO) director Plott bought 18,300 shares for $15.2K at $0.83
Profile
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
About Phio Pharmaceuticals Corp